AstraZeneca Stock And 2 AI Healthcare Shares Worth A Closer Look

Artificial intelligence in healthcare sits at the intersection of powerful data, pressing demographic trends and a world where central banks are still weighing inflation risks and growth signals. While inflation and interest rate paths remain uneven across regions, AI healthcare stocks in the Transformative AI Healthcare Stocks screener focus on companies using algorithms to improve diagnostics, treatment decisions and operational efficiency. This theme targets businesses that seek to cut costs and improve patient outcomes, which can matter across economic cycles. In this article you will see three stocks from the screener that show how this theme is playing out in practice.

IXICO (AIM:IXI)

Overview: IXICO is a London based AI healthcare company that runs an imaging and data analytics platform for clinical trials in neurological diseases such as Alzheimer’s, Huntington’s and Parkinson’s. It works with biopharma clients to collect, manage and analyse complex brain imaging and clinical data so they can design, run and interpret trials more efficiently.

Operations: IXICO currently generates about £7.3 million in revenue from Medical Labs & Research services.

Market Cap: £17.4 million

IXICO gives you focused exposure to AI in neuroimaging, which sits at the heart of drug development for complex brain disorders. Recent contracts, such as a £1.3 million deal for Alzheimer’s imaging analytics and a Parkinson’s research tie up with the Paris Brain Institute, show how its AI platform is being used in cutting edge studies. The trade off is clear. The company is still loss making, earnings are expected to decline and shareholders have faced dilution, all alongside board turnover and price volatility. For investors who can handle these risks, the mix of specialist expertise, respected partners and revenue growth to date may warrant a closer look.

IXICO’s specialist neuroimaging work with top research partners could be masking a much bigger story. Before evaluating whether the risks outweigh the potential, scan the 1 key reward and 4 important warning signs (2 are major!)

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge that discovers, develops, manufactures and sells prescription medicines across cancer, cardiovascular, kidney and metabolic diseases, respiratory and immunology, vaccines and rare diseases. Its portfolio includes widely used treatments such as Tagrisso, Imfinzi, Farxiga, Enhertu, Symbicort and a growing range of antibody drug conjugates and next generation therapies.

Operations: AstraZeneca generates about US$61.4b in revenue from pharmaceuticals.

Market Cap: £182.1b

AstraZeneca sits at the centre of the AI healthcare theme because it is pairing a deep oncology and rare disease pipeline with AI driven tools for drug discovery, trial design and response prediction, including work with Tempus, Pathos and Nucs AI. Analysts highlight expectations for higher earnings, supported by high quality profits, strong return on equity and a broad set of recent approvals such as Etcamah and expanded uses for Enhertu and Imfinzi. However, the stock also carries risks from high debt, heavy R&D spend and dependence on blockbuster drugs that may face future pricing pressure and biosimilar competition. The recent megamerger talks with Bristol Myers Squibb add another layer that close followers of AstraZeneca may wish to monitor.

AstraZeneca’s AI powered pipeline, blockbuster portfolio and recent approvals are only half the story. To see how debt, R&D intensity and blockbuster risk really fit together, review the 4 key rewards and 2 important warning signs

EMV Capital (AIM:EMVC)

Overview: EMV Capital is a London based venture capital company that backs early and mid stage businesses in areas such as digital health, diagnostics, therapeutics, robotics, AI and other healthcare technologies that aim to improve outcomes for people with chronic diseases. It typically invests up to £15 million in companies across the UK, Europe and the United States and prefers to hold controlling interests through its own balance sheet.

Operations: EMV Capital currently generates about £2.87 million in revenue from diagnostic kits and equipment, with most of this coming from the United Kingdom and smaller contributions from Europe, the United States and the rest of the world.

Market Cap: £15.1 million

EMV Capital provides exposure to a portfolio of digital health, diagnostics and therapeutics ventures rather than a single product pipeline. The company currently has a price-to-sales ratio that sits below some peers and has reported a reduced loss in 2025. At the same time, EMV Capital remains loss making, has less than a year of cash runway and its auditor has flagged doubts about its ability to continue as a going concern. With a new high profile chair and a valuation that has been compared to certain cash flow estimates, the next AGM and funding decisions could be particularly important for the business.

EMV Capital’s reduced loss and lower price to sales ratio suggest investors might be missing something in this portfolio story. To see how the optimism compares with funding pressure and going concern flags, go to the 3 key rewards and 2 important warning signs

The three stocks discussed here are just a starting point, and the full Transformative AI Healthcare Stocks screener on Simply Wall St has identified three more companies in the Transformative Artificial intelligence (AI) Healthcare Stocks screener with equally compelling AI healthcare narratives. Use the platform to analyze these stocks side by side, filter for the specific catalysts and healthcare AI themes that matter to you, and identify ideas for your own watchlist.

Take Control of Your Investment Journey

If IXICO or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond AI Healthcare?

Some of the most interesting stock stories move quickly. Use carefully filtered lists of fresh ideas before the crowd catches on, while the data still matters. Act now.

• Spot companies with strong dividends and solid balance sheets before income hunters pile in by scanning the curated 4 dividend fortresses, which screens for durability as well as yield.
• Chase early momentum in quality miners by reviewing the curated 32 elite gold producer stocks, which focuses on producers with meaningful scale and cleaner financial profiles.
• Hunt for resilience when markets wobble by checking the hand picked 7 resilient stocks with low risk scores, chosen for sturdier balance sheets and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com